Prognostic Implications of AccuFFRangio-based Functional Evaluation for Guiding Coronary Intervention for Non-IRA Stenosis in Patients With STEMI
试验速览
- 阶段
- 不适用
- 入组人数
- 500
- 主要终点
- Vessel-oriented composite endpoints (VOCEs)
研究概览
简要总结
This is a prospective, single-center clinical trial. AccuFFRangio (ArteryFlow Technology Co., Ltd., Hangzhou, China) is a novel method for evaluating the functional significance of coronary stenosis by computing the pressure in the vessel based on angiographic images. The aim of this study was to evaluate the diagnostic accuracy and prognostic implications of AccuFFRangio in patients with ST-segment elevation myocardial infarction (STEMI).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 Years and older
- •STEMI patients with primary percutaneous coronary intervention within 24 hours with at least 1 non-IRA
- •Diameter stenosis of 50%-90% by visual estimate
- •Reference vessel size > 2 mm in stenotic segment by visual estimate
排除标准
- •LVEF ≤ 40%
- •eGFR < 60 mL/min
- •Allergy to contrast media, adenosine
- •Prior CABG
结局指标
主要结局
Vessel-oriented composite endpoints (VOCEs)
时间窗: 1 year
Composite of vessel-related cardiovascular death, vessel-related myocardial infarction, and ischemia-driven target vessel revascularization.
Post-PCI AccuFFRangio
时间窗: 1 year
AccuFFRangio limits to yield no VOCEs (Composite of vessel-related cardiovascular death, vessel-related myocardial).
次要结局
- Cost analysis(1 year)
- Prognostic implications(1 year)